增生性糖尿病视网膜病变患者玻璃体内注射贝伐单抗后虹膜新生血管退行

• 作 者: Oshima Y. Sakaguchi H. Gomi F. Tano Y. 曹绪胜
• 机 构: Department of Ophthalmology Osaka University Medical School,Suita,Osaka,Japan Dr.,
• 出 处: 世界核心医学期刊文摘.眼科学分册
• 发表日期: 2006年11期
• 关键词: 玻璃体内注射 虹膜新生血管 贝伐单抗 荧光素 干预性 血管造影 炎症反应 对照性

Purpose:To assess the short-term safety and efficacy of intravitreal injection of bevacizumab for iris neovascularization(INV) .Design:Noncomparative,interventional case series.Methods:Intravitreal bevacizumab was injected in seven eyes of five patients with INV that was associated with proliferative diabetic retinopathy(PDR) .The main outcome measurements were visual acuity,intraocular pressure(IOP) ,and regression of INV by fluorescein angiography before and one week,one month,and two months after injection.Results:Regression of INV was confirmed in all eyes(100%) from one week after injection.Repeated injections stabilized the recurrence(two eyes;29%) that was observed two months after the initial injection.The visual acuity remained stable or improved,and the intraocular pressure was controlled in six eyes(86%) throughout the follow-up period.No inflammation or complications were observed.Conclusions:Intravitreal injection of bevacizumab may be an effective and safe alternative for patients with INV that is refractory to conventional treatments.

Purpose: To assess the short-term safety and efficacy of intravitreal injection of bevacizumab for iris neovascularization (INV). Design: Noncomparative, interventional case series. Methods: Intravitreal bevacizumab was injected in seven eyes of five patients with INV that was associated with proliferative diabetic retinopathy (PDR) .The main outcome measurements were visual acuity, intraocular pressure (IOP), and regression of INV by fluorescein angiography before and one week, one month, and two months after injection. Results: Regression of INV was confirmed in all eyes (100%) from one week after injection. Repeated injections stabilized the recurrence (two eyes; 29%) that was observed two months after the initial injection. visual acuity remained stable or improved, and the intraocular pressure was controlled in six eyes (86%) throughout the follow-up period. No inflammation or complications were observed. Conclusions: Intravitreal injection of bevacizumab may be an effective and safe alternative for patients with INV that is refractory to conventional treatments.